Stahel R A, Curioni-Fontecedro A, Rohrmann S, Dafni U, Sandner U, Opitz I, Andratschke N, Franzen D, Dimopoulou G, Matthes K L, Kohler M, Guckenberger M, Weder W
Comprehensive Cancer Center Zürich, University Hospital Zürich, Zurich, Switzerland.
Department of Medical Oncology and Hematology, University Hospital Zürich, Zurich, Switzerland.
Lung Cancer. 2020 Aug;146:217-223. doi: 10.1016/j.lungcan.2020.05.037. Epub 2020 Jun 7.
Cancer cases among the population of the canton Zurich, are registered in the Cancer Registry of the cantons of Zurich and Zug (KKR). The Thoracic Oncology Center, founded in 2011 is one of 17 multidisciplinary centers within the Comprehensive Cancer Center Zurich (CCCZ).
The aim of the current study is to quantify the mortality risk of patients with NSCLC and identify differences on survival and other factors between patients receiving their primary treatment at the CCCZ and those treated elsewhere and registered by KKR. The differential effect between CCCZ and KKR cohorts on survival: overall, by stage, sex and age, is explored. Stratified log-rank and Wilcoxon tests, Cox models and restricted mean survival times (RMST) are estimated. Propensity score matching (PSM) is also used to adjust for confounding factors.
Analysis included 848 NSCLC cases from the CCCZ and 1759 from the KKR, diagnosed between January 2011 and December 2015. At a median follow-up of 57 months, overall survival (OS) was significantly superior for patients treated at the CCCZ compared to KKR [Median OS: 36.0 months (95%CI: 31.0-45.0) and 12.0 months (95%CI: 11.0-13.0), respectively, stratified log-rank p < 0.001; adjusted HR = 1.31, (95% CI: 1.18-1.46), difference in RMST up to 72 months: 13.8 months (95%CI: 11.5-16.2), p < 0.001]. The effect of cohort was significant for stages III and IV (overall and also by sex and age). After PSM OS remained significantly superior for patients treated at the CCCZ compared to KKR.
The survival probability for patients in the CCCZ cohort was superior to that of patients in the canton Zürich treated outside the center. This analysis provides further evidence of the importance of the volume of experience and the availability of a multidisciplinary organization and research environment, as delivered by a comprehensive cancer center, on the outcome of patients with NSCLC.
苏黎世州居民中的癌症病例在苏黎世和楚格州癌症登记处(KKR)登记。成立于2011年的胸科肿瘤中心是苏黎世综合癌症中心(CCCZ)内的17个多学科中心之一。
本研究的目的是量化非小细胞肺癌患者的死亡风险,并确定在CCCZ接受初始治疗的患者与在其他地方接受治疗并由KKR登记的患者在生存及其他因素方面的差异。探讨了CCCZ和KKR队列在生存方面的差异影响:总体、按分期、性别和年龄。估计分层对数秩检验和Wilcoxon检验、Cox模型以及受限平均生存时间(RMST)。倾向得分匹配(PSM)也用于调整混杂因素。
分析纳入了2011年1月至2015年12月期间诊断的来自CCCZ的848例非小细胞肺癌病例和来自KKR的1759例病例。中位随访57个月时,与KKR相比,在CCCZ接受治疗的患者的总生存期(OS)显著更长[中位OS分别为:36.0个月(95%CI:31.0 - 45.0)和12.0个月(95%CI:11.0 - 13.0),分层对数秩检验p < 0.001;调整后HR = 1.31,(95%CI:1.18 - 1.46),直至72个月的RMST差异:13.8个月(95%CI:11.5 - 16.2),p < 0.001]。队列效应在III期和IV期(总体以及按性别和年龄)显著。PSM后,与KKR相比,在CCCZ接受治疗的患者的OS仍然显著更长。
CCCZ队列患者的生存概率优于苏黎世州中心外接受治疗的患者。该分析进一步证明了综合癌症中心所提供的经验量以及多学科组织和研究环境对非小细胞肺癌患者结局的重要性。